DLL3, a pariah antigen after the implosion of Abbvie’s Rova-T, holds the interest of a handful of industry players.
Abbvie’s decades-old work into Bcl-2 inhibition gave rise to Venclexta, but the group has gone back to studying a Venclexta predecessor compound.
New extended consensus forecasts from Evaluate Pharma show Roche edged out of first place by Abbvie as new blood replaces Humira.
Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?
Spending heavily on buybacks and dividends does not mean sector-leading share price performance, Evaluate Vantage finds.